Pfizer Management
Management criteria checks 3/4
Pfizer's CEO is Albert Bourla, appointed in Jan 2019, has a tenure of 6.17 years. total yearly compensation is $24.65M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.007% of the company’s shares, worth $9.59M. The average tenure of the management team and the board of directors is 5.9 years and 8.1 years respectively.
Key information
Albert Bourla
Chief executive officer
US$24.6m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 6.2yrs |
| CEO ownership | 0.007% |
| Management average tenure | 5.9yrs |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Pfizer: Undervalued Safe Haven In Risk-Off Market
Mar 11Pfizer Remains A Good Pick For Dividend Investors
Mar 04Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)
Feb 28
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Feb 19Pfizer: 3 Key Risks That Warrant A Sell
Feb 12Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Feb 04These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively
Feb 04Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Jan 28Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's
Jan 13Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Jan 13Pfizer: One Of The Next Big AI Winners
Dec 30Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year
Dec 30Pfizer: Time And Patience Ran Out (Rating Downgrade)
Dec 24Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call
Dec 18Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43
Dec 16Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Dec 11Pfizer: Too Cheap To Ignore
Dec 05Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Nov 21Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer
Nov 15Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings
Nov 13Pfizer: Discounted For A Reason - But Dividend Story Remains Rich
Nov 08Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 01Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
Oct 29Pfizer: Activists Clouding A Promising Picture
Oct 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$25m | US$2m | US$8b |
| Sep 29 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | -US$3b |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$22m | US$2m | US$2b |
| Oct 01 2023 | n/a | n/a | US$10b |
| Jul 02 2023 | n/a | n/a | US$21b |
| Apr 02 2023 | n/a | n/a | US$29b |
| Dec 31 2022 | US$33m | US$2m | US$31b |
| Oct 02 2022 | n/a | n/a | US$30b |
| Jul 03 2022 | n/a | n/a | US$29b |
| Apr 03 2022 | n/a | n/a | US$25b |
| Dec 31 2021 | US$24m | US$2m | US$22b |
| Oct 03 2021 | n/a | n/a | US$19b |
| Jul 04 2021 | n/a | n/a | US$12b |
| Apr 04 2021 | n/a | n/a | US$9b |
| Dec 31 2020 | US$21m | US$2m | US$7b |
| Sep 27 2020 | n/a | n/a | US$212m |
| Jun 28 2020 | n/a | n/a | US$7b |
| Mar 29 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$18m | US$2m | US$11b |
| Sep 29 2019 | n/a | n/a | US$16b |
| Jun 30 2019 | n/a | n/a | US$13b |
| Mar 31 2019 | n/a | n/a | US$11b |
| Dec 31 2018 | US$10m | US$1m | US$4b |
Compensation vs Market: Albert's total compensation ($USD24.65M) is above average for companies of similar size in the US market ($USD12.99M).
Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.
CEO
Albert Bourla (62 yo)
6.2yrs
Tenure
US$24,648,727
Compensation
Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and serves as its Chairman and director of the Board since January 2020 and had been its Executive D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.2yrs | US$24.65m | 0.0066% $ 9.6m | |
| CFO & Executive VP | 2.8yrs | US$8.12m | 0.00067% $ 976.6k | |
| Chief Scientific Officer and President of Research & Development | less than a year | US$7.85m | 0.0029% $ 4.2m | |
| Senior VP | 5yrs | no data | 0.00021% $ 306.1k | |
| Executive VP and Chief Digital & Technology Officer | 6.2yrs | no data | 0.00074% $ 1.1m | |
| Chief Investor Relations Officer | no data | no data | no data | |
| Executive VP & Chief Legal Officer | 11.3yrs | US$5.48m | 0.0028% $ 4.1m | |
| Chief People Experience Officer & Executive VP | 4.8yrs | no data | 0.00069% $ 1.0m | |
| Executive VP & Chief Corporate Affairs Officer | 17.1yrs | no data | 0.0030% $ 4.4m | |
| Senior VP and Chief Scientific Officer of Inflammation & Immunology | 8.8yrs | no data | no data | |
| Chief Scientific Officer of Oncology | 5.7yrs | no data | no data | |
| Senior VP & Chief Scientific Officer of Rare Disease | no data | no data | no data |
5.9yrs
Average Tenure
58.5yo
Average Age
Experienced Management: PFE's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 5.2yrs | US$24.65m | 0.0066% $ 9.6m | |
| Lead Independent Director | 11.5yrs | US$445.00k | no data | |
| Independent Director | 8.1yrs | US$360.00k | 0.00057% $ 830.9k | |
| Independent Director | 17.5yrs | US$410.00k | 0.00018% $ 262.4k | |
| Independent Director | 10.8yrs | US$390.00k | 0.000060% $ 87.5k | |
| Member of Emerging Markets Advisory Board | no data | no data | no data | |
| Independent Director | 5yrs | US$363.00k | no data | |
| Independent Director | 7yrs | US$380.00k | no data | |
| Independent Director | 5.1yrs | US$380.00k | no data | |
| Independent Director | 5.8yrs | US$390.00k | 0.00018% $ 262.4k | |
| Independent Director | 9.8yrs | US$390.00k | no data | |
| Independent Director | 13.3yrs | US$410.00k | no data |
8.1yrs
Average Tenure
65.5yo
Average Age
Experienced Board: PFE's board of directors are considered experienced (8.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 07:50 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 50 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Alistair Campbell | Berenberg |
| Luisa Hector | Berenberg |